An interesting comment somebody posted in SA
Post# of 153802
(Total Views: 692)
Posted On: 01/26/2020 3:26:18 PM
An interesting comment somebody posted in SA
The science is crystal clear and compelling. All boxes are checked for FDA approval of the Breakthrough Therapy Designation for Leronlimab for metastatic Triple Negative Breast Cancer and additionally Metastatic Breast Cancer. There is leeway allowed to the FDA in their decision and what they are bound to be looking for in the few weeks before D Day is whether or not the next few patients respond similarly as the existing patients, and also that the progression of all or at least most patients continues favorably.
Management has been highly respectful of the FDA, entirely open and forthcoming, and the FDA are not a bunch of bigots who discount science because the applicant's CEO has an accent, which is what I suspect is the bases for those who slander Dr. Pourhassan, who is a man of extraordinary integrity and competence. For those of you who have never been CEO of a successful technology development company as I have, are thinking about investing in CYDY, and are wondering whose opinion in this matter you are able to trust, let me give you a clue...... trust Samsung's. They are the big drug manufacturer who so believe CYDY's science that they agreed to manufacture and provide to CYDY one billion US dollars worth of Leronlimab WITH NO PAYMENT UP FRONT, JUST PAY AS THEY SELL. Thus, CYDY can check that box on the FDA requirements (need to have on hand a large enough volume of product to meet anticipated patient needs and ability to make more in order to check one of the boxes for approval). Samsung, with all their experience, expertise, scientific staff and FDA compliance professionals, they are your expert due diligence. You can ride their coattails. You don't have to believe me, even though the private fund I manage gained over 140 percent in 2019 and I personally more than tripled my net worth in a lesser period of time, all in biotechnology. You don't have to trust the author, Theodore Zucconi, who has been a successful biotechnology CEO (even though I do), you have all of Samsung's experts decision available to you, for free. Take advantage of it. That's the best way to use this forum. The naysayers in this case, if you looked into their successes as a group, most likely don't beat the market and should never be making their own decisions. They already lost their chances to be easy millionaires by slandering CYDY and Dr. Pourhassan, as is just, and they likely shall continue to loose. The only thing that you need to watch for now in the near future is how do the new and ongoing mTNBC and MBC patients fare. However, the biggest money in this case is made by understanding that the science that already has occurred is highly likely to continue occurring. The train is definitely leaving the station. Congratulations to rpoe and those of you who have the humility to have seen that and gotten on board. There's still plenty of room for this stock to run, but every increase at the low price end magnifies at the higher price end. So, if you are here to earn real money and change your life, think about that. Otherwise, you are probably better off investing in a fund managed by someone other than yourself.
The science is crystal clear and compelling. All boxes are checked for FDA approval of the Breakthrough Therapy Designation for Leronlimab for metastatic Triple Negative Breast Cancer and additionally Metastatic Breast Cancer. There is leeway allowed to the FDA in their decision and what they are bound to be looking for in the few weeks before D Day is whether or not the next few patients respond similarly as the existing patients, and also that the progression of all or at least most patients continues favorably.
Management has been highly respectful of the FDA, entirely open and forthcoming, and the FDA are not a bunch of bigots who discount science because the applicant's CEO has an accent, which is what I suspect is the bases for those who slander Dr. Pourhassan, who is a man of extraordinary integrity and competence. For those of you who have never been CEO of a successful technology development company as I have, are thinking about investing in CYDY, and are wondering whose opinion in this matter you are able to trust, let me give you a clue...... trust Samsung's. They are the big drug manufacturer who so believe CYDY's science that they agreed to manufacture and provide to CYDY one billion US dollars worth of Leronlimab WITH NO PAYMENT UP FRONT, JUST PAY AS THEY SELL. Thus, CYDY can check that box on the FDA requirements (need to have on hand a large enough volume of product to meet anticipated patient needs and ability to make more in order to check one of the boxes for approval). Samsung, with all their experience, expertise, scientific staff and FDA compliance professionals, they are your expert due diligence. You can ride their coattails. You don't have to believe me, even though the private fund I manage gained over 140 percent in 2019 and I personally more than tripled my net worth in a lesser period of time, all in biotechnology. You don't have to trust the author, Theodore Zucconi, who has been a successful biotechnology CEO (even though I do), you have all of Samsung's experts decision available to you, for free. Take advantage of it. That's the best way to use this forum. The naysayers in this case, if you looked into their successes as a group, most likely don't beat the market and should never be making their own decisions. They already lost their chances to be easy millionaires by slandering CYDY and Dr. Pourhassan, as is just, and they likely shall continue to loose. The only thing that you need to watch for now in the near future is how do the new and ongoing mTNBC and MBC patients fare. However, the biggest money in this case is made by understanding that the science that already has occurred is highly likely to continue occurring. The train is definitely leaving the station. Congratulations to rpoe and those of you who have the humility to have seen that and gotten on board. There's still plenty of room for this stock to run, but every increase at the low price end magnifies at the higher price end. So, if you are here to earn real money and change your life, think about that. Otherwise, you are probably better off investing in a fund managed by someone other than yourself.
(9)
(0)